APA (7th ed.) Citation

SY, H., SS, Y., K, S., WJ, C., CS, C., RS, W., . . . CK, M. (2020). Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis. Advances in therapy, 37(7), 3404. https://doi.org/10.1007/s12325-020-01395-x

Chicago Style (17th ed.) Citation

SY, Huang, et al. "Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis." Advances in Therapy 37, no. 7 (2020): 3404. https://doi.org/10.1007/s12325-020-01395-x.

MLA (9th ed.) Citation

SY, Huang, et al. "Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis." Advances in Therapy, vol. 37, no. 7, 2020, p. 3404, https://doi.org/10.1007/s12325-020-01395-x.